The sodium iodide Symporter (NIS) and potential regulators in normal, benign and malignant human breast tissue

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Ryan, James ^a   Curran, Catherine E ^a   Hennessy, Emer ^a   Newell, John ^a   Morris, John C ^b   Kerin, Michael J ^a   Dwyer, Roisin M ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RNA; SODIUM IODIDE SYMPORTER; THYROID HORMONE; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA; THYROXINE; COTRANSPORTER;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST FIBROADENOMA; CANCER CELL CULTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; TISSUE DISTRIBUTION; TISSUE SECTION; UPREGULATION; BREAST TUMOR; DRUG EFFECT; FIBROADENOMA; GENETICS; MAMMARY GLAND; METABOLISM; PATHOLOGY;

BREAST NEOPLASMS; ESTRADIOL; FEMALE; FIBROADENOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY GLANDS, HUMAN; SYMPORTERS; THYROID HORMONES; THYROXINE; TRETINOIN;

EID: 79251648045     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016023     Document Type: Article

References (35)

1. Dohán O, De la Vieja A, Paroder V, Riedel C, Artani M, et al. (2003) The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 24: 48-77.
2. Tazebay U, Wapnir I, Levy O, Dohan O, Zuckier L, et al. (2000) The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 6: 871-878.
3. Kilbane M, Ajjan R, Weetman A, Dwyer R, McDermott E, et al. (2000) Tissue iodine content and serum-mediated 125I uptake-blocking activity in breast cancer. J Clin Endocrinol Metab 85: 1245-1250.
4. Upadhyay G, Singh R, Agarwal G, Mishra S, Pal L, et al. (2003) Functional expression of sodium iodide symporter (NIS) in human breast cancer tissue. Breast Cancer Res Treat 77: 157-165.
5. Rudnicka L, Sińczak A, Szybiński P, Huszno B, Stachura J (2003) Expression of the Na(+)/I(2) symporter in invasive ductal breast cancer. Folia Histochem Cytobiol 41: 37-40.
6. Wapnir I, van de Rijn M, Nowels K, Amenta P, Walton K, et al. (2003) Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab 88: 1880-1888.
7. Renier C, Yao C, Goris M, Ghosh M, Katznelson L, et al. (2009) Endogenous NIS expression in triple-negative breast cancers. Ann Surg Oncol 16: 962-968.
8. Moon D, Lee S, Park K, Park K, Ahn S, et al. (2001) Correlation between 99mTc-pertechnetate uptakes and expressions of human sodium iodide symporter gene in breast tumor tissues. Nucl Med Biol 28: 829-834.
9. Wapnir I, Goris M, Yudd A, Dohan O, Adelman D, et al. (2004) The Na+/I2 symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. Clin Cancer Res 10: 4294-4302.
10. Renier C, Vogel H, Offor O, Yao C, Wapnir I (2010) Breast cancer brain metastases express the sodium iodide symporter. J Neurooncol 96: 331-336.
11. Berger F, Unterholzner S, Diebold J, Knesewitsch P, Hahn K, et al. (2006) Mammary radioiodine accumulation due to functional sodium iodide symporter expression in a benign fibroadenoma. Biochem Biophys Res Commun 349: 1258-1263.
12. Willhauck MJ, DJ OK, Wunderlich N, Goke B, Spitzweg C (2011) Stimulation of retinoic acid-induced functional sodium iodide symporter (NIS) expression and cytotoxicity of (131)I by carbamazepine in breast cancer cells. Breast Cancer Res Treat 125: 377-386.
13. Willhauck M, Sharif-Samani B, Senekowitsch-Schmidtke R, Wunderlich N, Göke B, et al. (2008) Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone. Breast Cancer Res Treat 109: 263-272.
14. Riesco-Eizaguirre G, Santisteban P (2006) A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol 155: 495-512.
15. Suzuki K, Lavaroni S, Mori A, Ohta M, Saito J, et al. (1998) Autoregulation of thyroid-specific gene transcription by thyroglobulin. Proc Natl Acad Sci U S A 95: 8251-8256.
16. Suzuki K, Mori A, Saito J, Moriyama E, Ullianich L, et al. (1999) Follicular thyroglobulin suppresses iodide uptake by suppressing expression of the sodium/ iodide symporter gene. Endocrinology 140: 5422-5430.
17. Kogai T, Kanamoto Y, Li A, Che L, Ohashi E, et al. (2005) Differential regulation of sodium/iodide symporter gene expression by nuclear receptor ligands in MCF-7 breast cancer cells. Endocrinology 146: 3059-3069.
18. Alotaibi H, Yaman E, Demirpençe E, Tazebay U (2006) Unliganded estrogen receptor-alpha activates transcription of the mammary gland Na+/I2 symporter gene. Biochem Biophys Res Commun 345: 1487-1496.
19. Knostman K, Cho J, Ryu K, Lin X, McCubrey J, et al. (2004) Signaling through 39,59-cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer. J Clin Endocrinol Metab 89: 5196-5203.
20. Knostman K, McCubrey J, Morrison C, Zhang Z, Capen C, et al. (2007) PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer. BMC Cancer 7: 137.
21. Martínez-Iglesias O, Garcia-Silva S, Tenbaum S, Regadera J, Larcher F, et al. (2009) Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Res 69: 501-509.
22. Silva J, Domínguez G, González-Sancho J, García J, Silva J, et al. (2002) Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene 21: 4307-4316.
23. Conde I, Paniagua R, Zamora J, Blánquez M, Fraile B, et al. (2006) Influence of thyroid hormone receptors on breast cancer cell proliferation. Ann Oncol 17: 60-64.
24. McNeill R, Miller N, Kerin M (2007) Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer. BMC Mol Biol 8: 107.
25. Livak K, Schmittgen T (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(2Delta Delta C(T)) Method. Methods 25: 402-408.
26. Castro M, Bergert E, Beito T, McIver B, Goellner J, et al. (1999) Development of monoclonal antibodies against the human sodium iodide symporter: immunohistochemical characterization of this protein in thyroid cells. J Clin Endocrinol Metab 84: 2957-2962.
27. Dohán O, Carrasco N (2003) Advances in Na(+)/I(2) symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol 213: 59-70.
28. Alotaibi H, Yaman E, Salvatore D, Di Dato V, Telkoparan P, et al. (2010) Intronic elements in the Na+/I2 symporter gene (NIS) interact with retinoic acid receptors and mediate initiation of transcription. Nucleic Acids Res 38: 3172-3185.
29. Ohashi E, Kogai T, Kagechika H, Brent G (2009) Activation of the PI3 kinase pathway by retinoic acid mediates sodium/iodide symporter induction and iodide transport in MCF-7 breast cancer cells. Cancer Res 69: 3443-3450.
30. Gol Choe J, Kim Y, Kim K, Choo H, Shin J, et al. (2005) Altered gene expression profiles by sodium/iodide symporter gene transfection in a human anaplastic thyroid carcinoma cell line using a radioactive complementary DNA microarray. Nucl Med Commun 26: 1155-1162.
31. Wallden B, Emond M, Swift M, Disis M, Swisshelm K (2005) Antimetastatic gene expression profiles mediated by retinoic acid receptor beta 2 in MDA-MB-435 breast cancer cells. BMC Cancer 5: 140.
32. Silva E, Tornos C, Malpica A, Deavers M, Tortolero-Luna G, et al. (2002) The association of benign and malignant ovarian adenofibromas with breast cancer and thyroid disorders. Int J Surg Pathol 10: 33-39.
33. Nagaya T, Jameson J (1993) Thyroid hormone receptor dimerization is required for dominant negative inhibition by mutations that cause thyroid hormone resistance. J Biol Chem 268: 15766-15771.
34. Lee S, Privalsky M (2005) Heterodimers of retinoic acid receptors and thyroid hormone receptors display unique combinatorial regulatory properties. Mol Endocrinol 19: 863-878.
35. Barton KN, Stricker H, Brown SL, Elshaikh M, Aref I, et al. (2008) Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther 16: 1761-1769.